GLP-1 Agonists Show Promise in Reducing Glaucoma Risk in Patients with Diabetes

A systematic review and meta-analysis found that GLP-1 receptor agonists used in type 2 diabetes treatment may be associated with a reduced risk of glaucoma. The analysis revealed a potential drop inIOP and highlighted anti-inflammatory and neuroprotective effects. Although findings are encouraging, significant heterogeneity warrants cautious interpretation and underscores the need for further large-scale, controlled trials. Photo: Novo Nordisk. Click image to enlarge. As the use of glucagon-like peptide-1 (GLP-1) receptor agonists has grown considerably over the past decade, evidence suggests they can influence more than just the regulation of glucose levels. Patients with type 2 diabetes who also take a GLP-1 drug are less likely to develop dry eye disease compared to those on metformin, and other research shows these therapies can influence the course of various ocular conditions. For instance, they may also have vascular-protective properties.Considering that type 2 diabetes increases the risk of both primary open-angle glaucoma (POAG) and neovascular glaucoma, a group of researchers investigated the incidence of these diseases in patients taking GLP-1 receptor agonists. Their results, recently published in the journal Endocrinology, Diabetes & Metabolism, showed there may be a lowered risk of glaucoma in some circumstances; they caution, however, that further studies are needed.In this systematic review and meta-analysis a total of 12 studies were found, encompassing over 2.5 million participants. Data analysis employed the random-effects model, presenting odds ratios (OR) with 95% confidence intervals (CI). The meta-analysis indicated that GLP-1 agonist use was associated with a non–statistically significant reduction in the incidence of glaucoma (OR: 0.78). Sensitivity analysis did show a significant reduction of glaucoma in GLP-1 receptor agonist users compared to other anti-hyperglycemics (OR: 0.70; 95% CI: 0.52 to 0.92) that was observed to be significant.Some of the noteworthy findings of the studies highlighted by the researchers in their paper included the relationship between GLP-1 drugs and changes in intraocular pressure (IOP). Comparing individuals on GLP-1 drugs to those on other antidiabetic drugs, results showed that the former “had a decreased probability of receiving a new glaucoma diagnosis,” wrote the authors of this meta-analysis. The study also revealed a statistically significant drop in IOP after starting GLP-1 receptor agonist treatment, “especially in those with a history of glaucoma or pre-existing excessive IOP.”The researchers also found that GLP-1 agonist use in the management of type 2 diabetes may have possible cardiovascular advantages; therefore, reductions in blood pressure and improved lipid profiles may indirectly improve ocular health. “These systemic advantages are important because they may help people with diabetes to experience fewer ocular problems,” they wrote. This class of drugs has a variety of actions, the researchers wrote, “including those that affect inflammation and insulin sensitivity, which makes them useful tools for managing diabetes and preventing eye disorders.”Specific to glaucoma risk, underlying mechanisms of GLP-1 agonist use involve enhancement of insulin sensitivity, reduction of inflammation and promotion of neuroprotection. “Given that insulin resistance and hyperglycemia are established risk factors for the development of diabetic retinopathy and possibly glaucoma, this improvement in insulin sensitivity is noteworthy,” the authors wrote, speculating that this class of drugs “may significantly lower the incidence of diabetic eye problems by enhancing metabolic indices.” Additionally, the anti-inflammatory properties may be involved in shielding retinal neurons from glaucomatous damage, they continued.This is the only meta-analysis to date conducted on this topic, although the authors say their results should be interpreted with caution due to the observational design of the studies included in the review. Furthermore, the heterogeneity was considerable and follow-up lengths varied from three years to 12. Ultimately, these findings suggest promising implications for future glaucoma management in patients with diabetes, the authors concluded in the journal. They argue for continued research focused on long-term effects and large-scale clinical trials with uniform protocols. Such efforts, they speculate, “may lead to the development of targeted therapies aimed at preventing glaucoma.”Click here for the journal source. Asif M, Asif A, Rahman UA, Farooqi HA, Fatima O, Ali W, Jafar U, and Jaber MH. Incidence of glaucoma in type 2 diabetes patients treated with GLP-1 receptor agonists: A systematic review and meta-analysis. Endocrinol Diab Metab. June 13, 2025. [Epub ahead of print.]